Get the Stockscreener App
5.00
2.53%
-0.13
After Hours:
5.00
Alvotech stock is traded at $5.00, with a volume of 317.65K.
It is down -2.53% in the last 24 hours and up +8.70% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
See More
Previous Close:
$5.13
Open:
$5.14
24h Volume:
317.65K
Relative Volume:
0.55
Market Cap:
$1.56B
Revenue:
$391.87M
Net Income/Loss:
$-441.45M
P/E Ratio:
-2.7027
EPS:
-1.85
Net Cash Flow:
$-301.21M
1W Performance:
-4.94%
1M Performance:
+8.70%
6M Performance:
-44.01%
1Y Performance:
-62.01%
1-Day Range:
$4.96
$5.14
1-Week Range:
$4.96
$5.23
52-Week Range:
$4.32
$13.70
Alvotech Stock (ALVO) Company Profile
Compare ALVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
5.00 | 1.60B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
125.92 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.00 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.95 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
496.72 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Nov-04-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-14-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech (NasdaqGM:ALVO) Valuation Check After New $100 Million GoldenTree Term Loan for Biosimilar Growth - Yahoo Finance UK
The Truth About Alvotech: Why Everyone on Wall Street Suddenly Cares - AD HOC NEWS
Alvotech Stock Analysis and ForecastInstitutional Buying Trends & Free Superior Profit Margins - earlytimes.in
Alvotech secures USD 100M term loan - Medical Buyer
Alvotech Raises USD 100 Million Term Loan to Bolster Biosimilar Growth and 2026 Launches - TipRanks
Alvotech’s Volatile Ascent: Can A High?Beta Biosimilar Pure Play Keep Its Momentum? - AD HOC NEWS
Alvotech secures $100 million loan facility - Biostock
Icelandic BioTech Alvotech secures €100 million term loan facility to bolster liquidity and R&D investment - EU-Startups
What analysts say about Alvotech Z45 stockEarnings Forecast Updates & Double Digit Returns - earlytimes.in
Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in US - MSN
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged ... - Bluefield Daily Telegraph
ALVO Investor News: If You Have Suffered Losses in Alvotech - GlobeNewswire
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Alvotech Secures USD 100 Million Senior Term Loan to Enhance Liquidity and Support R&D Initiatives - Quiver Quantitative
Alvotech Secures Term Loan Facility of USD 100 Million - The Manila Times
Alvotech (NASDAQ:ALVO) Trading 2.9% HigherShould You Buy? - MarketBeat
Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - PR Newswire
Alvotech announced that it has received $100 million in funding - marketscreener.com
The Technical Signals Behind (ALVO) That Institutions Follow - Stock Traders Daily
Alvotech Files Notification with CSSF Regarding Changes in Own Shares - Quiver Quantitative
Changes in company's own shares - marketscreener.com
Alvotech : Changes in company's own shares - marketscreener.com
Alvotech : Acquisition or disposal of the issuer's own sharesALVOTECH - marketscreener.com
EV Market: Why Alvotech stock is favored by top institutionsMarket Sentiment Review & Growth Oriented Trading Recommendations - moha.gov.vn
Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Why Bolt Projects Holdings Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket - Benzinga
Alvotech (NASDAQ:ALVO) Short Interest Down 41.1% in December - MarketBeat
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - ACCESS Newswire
Is Alvotech stock near bottom after declineSwing Trading Watchlist & Build Wealth Brick by Brick With Us - bollywoodhelpline.com
Alvotech Investor News: Rosen Law Firm Encourages Alvotech Inves - GuruFocus
Alvotech (NASDAQ:ALVO) Trading Up 6.8%Time to Buy? - MarketBeat
Alvotech (ALVO): Firm reaffirms 2025 growth outlook - MSN
Alvotech Begins European Rollout of First-Ever Simponi Biosimilar Gobivaz - TipRanks
Why Alvotech (ALVO) Is Down 8.5% After Securing a 2026 US Entry Window for AVT06 - simplywall.st
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma - Sahm
Alvotech announces European launch of biosimilar to Simponi - MSN
Alvotech/Advanz First to Launch Golimumab Biosimilar Worldwide - Pearce IP
Alvotech’s Financial Calendar for 2026 - The Manila Times
Alvotech : Financial Calendar for 2026 - marketscreener.com
Alvotech rolls out first Simponi biosimilar across Europe - The Pharma Letter
Alvotech Launching Gobivaz Biosimilar in Europe - marketscreener.com
Alvotech Launches Gobivaz® (AVT05), First Biosimilar to Simponi®, with NHS England Tender Support - Quiver Quantitative
New Simponi lookalike drug rolls out in Europe with NHS backing - Stock Titan
Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06 - MSN
Fund Flows: Is Alvotech stock supported by strong fundamentalsMarket Risk Analysis & Real-Time Volume Analysis Alerts - moha.gov.vn
Alvotech (ALVO): Firm Reaffirms 2025 Growth Outlook - Finviz
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - ACCESS Newswire
Assessing Alvotech (NasdaqGM:ALVO)’s Valuation After FDA Setback and 2025 Guidance Cut - simplywall.st
Big Money Moves: Why retail investors favor Alvotech stockEarnings Miss & Short-Term Trading Opportunity Alerts - ulpravda.ru
Volume Recap: Why Alvotech Equity Warrant stock remains resilient2025 Market WrapUp & Long Hold Capital Preservation Tips - ulpravda.ru
Alvotech, Teva secure US settlement with Regeneron for Eylea biosimilar launch - Indian Pharma Post
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.19%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):